A carregar...
Population pharmacokinetics of exendin‐(9‐39) and clinical dose selection in patients with congenital hyperinsulinism
AIMS: Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycaemia in infants and children. Exendin‐(9‐39), an inverse glucagon‐like peptide 1 (GLP‐1) agonist, is a novel therapeutic agent for HI that has demonstrated glucose‐raising effect. We report the first population pha...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5809353/ https://ncbi.nlm.nih.gov/pubmed/29077992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13463 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|